Finance

Lists
LEGN:NASDAQ
Legend Biotech Corp
$19.11
+0.26%
(+0.050) 1D
$18.97
-0.73% (-0.14)
After hours
Closed: Sep 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LEGN...
Open
$19.49
High
$19.69
Low
$18.85
Mkt. cap
3.72B
Avg. vol.
2.10M
Volume
1.43M
52-wk high
$37.46
52-wk low
$16.25
EPS
-$0.50
Beta
0.40
Shares outstanding
193.44M
No. of employees
3K
Open
$19.49
High
$19.69
Low
$18.85
Mkt. cap
3.72B
Avg. vol.
2.10M
Volume
1.43M
52-wk high
$37.46
52-wk low
$16.25
EPS
-$0.50
Beta
0.40
Shares outstanding
193.44M
No. of employees
3K
News stories
From web sources and news partners
About Legend Biotech Corp
CEO-
Employees3.2K
FoundedNov 17, 2014
HeadquartersSomerset, New Jersey, United States
SectorBiotechnology
Websitelegendbiotech.com
Analyst ratings
Based on 9 analysts giving stock ratings to LEGN in the past 3 months
Buy
Buy
5
Hold
4
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for LEGN in the last 3 months.
Highest
Current $19.11
$74.00 (+287.23%)
Average
$45.86 (+139.98%)
Lowest
$24.00 (+25.59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Etzer Darout
Barclays
Buy
Maintained
$74.00
+287.2%
09/11/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$58.00
+203.5%
09/09/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$65.00
+240.1%
09/04/2026
Ashwani Verma
UBS
Hold
Reiterated
$28.00
+46.5%
08/13/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
$48.00
+151.2%
08/12/2026
Ziyi Chen
Goldman Sachs
Buy
Maintained
$40.70
+113%
08/12/2026
Kostas Biliouris
Oppenheimer
Hold
Downgraded
$40.00
+109.3%
08/12/2026
Yaron Werber
TD Cowen
Hold
Reiterated
$24.00
+25.6%
08/12/2026
Jessica Fye
J.P. Morgan
Hold
Initiated
$35.00
+83.2%
07/13/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$64.00
+234.9%
06/15/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
$70.00
+266.3%
03/13/2026
James Shin
Deutsche Bank
Buy
Reiterated
$60.00
+214%
03/09/2026
Qize Ding
Rothschild & Co Redburn
Hold
Downgraded
$24.00
+25.6%
02/12/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.32 / $0.28
+14.29%beat
Revenue / Est. (USD)
387.50M / 351.75M
+10.16%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
272.33M
306.38M
305.10M
387.50M
Cost of goods sold
115.31M
123.46M
175.90M
137.40M
Cost of revenue
115.31M
123.46M
175.90M
137.40M
Research and development expenses
113.15M
101.33M
85.70M
96.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87.33M
101.19M
90.10M
96.40M
Operating expense
200.48M
203.52M
179.00M
192.40M
Total operating expenses
315.78M
326.98M
354.90M
329.80M
Operating income
-43.45M
-20.60M
-49.80M
57.70M
Other non operating income
-654.00K
3.29M
-500.00K
-1.40M
EBT including unusual items
-39.07M
-19.60M
-53.10M
55.50M
EBT excluding unusual items
-39.07M
-20.57M
-53.10M
55.50M
Income tax expense
616.00K
11.22M
1.20M
22.30M
Effective tax rate
-1.58%
-57.23%
-2.26%
40.18%
Other operating expenses
-
1.00M
3.20M
-
Net income
-39.69M
-30.82M
-54.30M
33.20M
Net profit margin
-14.57%
-10.06%
-17.80%
8.57%
Earnings per share
-0.22
-0.16
-0.28
0.32
Interest and investment income
9.66M
7.95M
7.30M
5.60M
Interest expense
-4.50M
-7.80M
-4.20M
-3.90M
Net interest expenses
5.16M
150.00K
3.10M
1.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
-41.53M
-17.92M
-47.40M
61.70M
Gain or loss from assets sale
-250.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps